QUEENSBURY, N.Y., December 31, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the ...

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (DCTH) (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not ...

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.